病毒載體及質體DNA實驗服務的全球市場:市場規模、佔有率、預測、機會分析 - 各實驗服務、終端用戶
Viral Vector and Plasmid DNA Testing Services Market: by Testing Services, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
|出版商||Coherent Market Insights||商品編碼||931876|
|出版日期||內容資訊||英文 145 Pages
|病毒載體及質體DNA實驗服務的全球市場:市場規模、佔有率、預測、機會分析 - 各實驗服務、終端用戶 Viral Vector and Plasmid DNA Testing Services Market: by Testing Services, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027|
|出版日期: 2020年03月12日||內容資訊: 英文 145 Pages||
Viral vectors are the best approach used in the gene therapies and therefore, testing services are the key factors for the timely development of viral vector-based therapies. Viral vector characterization plays an important role for orthogonal analytical approaches. The characterization is significant through the regulatory perspective, which include product safety, identity, purity, and potency. Nowadays, viral vector are the leading vehicle for the multiple virus-based drugs, which are approved in the global market and are developed for various treatments such as cancer and neurology, hematology, ophthalmology, and metabolic or muscular disorders. Viral-based products has the promising future in the pharmaceutical sector for many innovations.
The ongoing clinical trials on the viral vectors and plasmid DNA for various treatment is expected to fuel growth of the market in the forecast period. For instance, according to data published in the Journal of Gene Medicine, March 2018, till November 2017, around 2,600 gene therapy clinical trials were ongoing that are approved in 36 countries which include the U.S., the U.K., Australia, Canada, China, France, Germany, Japan, Switzerland, the Netherlands, and others. Moreover, diseases targeted by gene therapies include cardiovascular diseases, cancer, inflammatory and infectious diseases, Hemophilia A and B, severe combined immunodeficiency (SCID), ocular diseases, neurological diseases, and others.
Furthermore, favorable regulations imposed by the regulatory authorities for the specific utilization of viral vectors or plasmid DNA in the industries are expected to fuel growth of the market. For instance, in March 2018, the European Medicines Agency (EMA) drafted a guideline on the quality, non-clinical, and clinical aspects of gene therapy medicinal products, wherein the agency stated that characterization studies should be conducted throughout the development process right from starting materials, intermediates, drug substance and drug product in the gene therapy medicinal products (GTMP). The agency also stated that the characterization of the vector should include all components, but in particular, those present in the final product to be administered.
The viral vector and plasmid DNA testing services market is expected to witness significant growth over the forecast period, owing to rising number of business expansion by opening a new center or process development service (PDS). For instance, in February 2019, LakePharma, Inc., a contract research, development, and manufacturing organization (CRDMO), announced the availability of its vector center commercially located at Worcester, U.S. for offering broad range of services such as viral vector production, CAR-T engineering, analytical development of vectors, and others. The company also made lentivirus, adeno-associated virus (AAV), and baculovirus production systems available at the center.
Moreover, acquisitions by the major players are expected to drive growth of viral vector and plasmid DNA testing services market over the forecast period. For instance, in November 2018, ABL Europe SAS, a subsidiary of ABL, Inc., acquired a former Accinov GMP manufacturing site located in Lyon, France for expansion of viral vector GMP contract manufacturing capacity in the gene therapy space. The site has 3 GMP suites, laboratory and office, which provides process development, and analytical support for gene therapy.
This report provides in-depth analysis of the viral vector and plasmid DNA testing services market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2019 -2027), considering 2018 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global viral vector and plasmid DNA testing services market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as part of this study include Charles River Laboratories, Inc., WuXi AppTec Co., Ltd., Cobra Biologics and Pharmaceutical Services, Merck KGaA, Lonza, Eurofins Scientific, FinVector Vision Therapies, Advanced Bioscience Laboratories, Inc., Takara Bio Inc., ViruSure GmbH, and Genezen Laboratories amongst others
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, technology upgradation, market expansion, and marketing tactics
The global viral vector and plasmid DNA testing services market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the viral vector and plasmid DNA testing services market